Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Core Insights - Biomea Fusion, Inc. will present new clinical data from the COVALENT-111 study at the ATTD 2025 conference, highlighting advancements in diabetes care [1][2] - The presentations will focus on the efficacy of icovamenib, a novel treatment aimed at enhancing beta cell function and glycemic control in type 2 diabetes patients [2][3] Presentation Details - Biomea will feature two oral presentations and one poster presentation, along with a symposium at the ATTD 2025 conference scheduled for March 19-22, 2025, in Amsterdam [1][4] - The oral presentations will cover the exploration of icovamenib in severe insulin-deficient type 2 diabetes and its combination with GLP-1 receptor agonists [4] - A poster presentation will evaluate the long-term efficacy and safety of short-term icovamenib treatment in type 2 diabetes patients [4] Clinical Findings - New clinical findings from the Expansion Phase of the COVALENT-111 study indicate that icovamenib treatment can lead to sustained improvements in glycemic control, even 14 weeks post-treatment [2][3] - Previous studies showed that 12 weeks of icovamenib treatment resulted in statistically significant reductions in HbA1c levels among insulin-deficient type 2 diabetes patients [3] Mechanism of Action - Icovamenib is designed to inhibit menin, which may enhance beta cell function and promote the regeneration of insulin-producing cells [7][10] - The mechanism of action suggests that icovamenib could serve as a first-in-class, disease-modifying therapy for type 1 and type 2 diabetes [10][11] Industry Context - Type 2 diabetes is a significant global health issue, affecting over 100 million adults worldwide, with a pressing need for effective treatments [3][9] - The economic burden of diabetes care is substantial, with one in four healthcare dollars in the U.S. spent on diabetes-related expenses [9]